• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Dirk Strumberg, Heike Richly, +12 authors Siegfried Seeber
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Published: 10 February 2005)
  • PURPOSE BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established theContinue Reading
  • Volker Sadony, M. Körber, +5 authors Max Ernst Scheulen
  • Medicine
  • European journal of cardio-thoracic surgery…
  • 1998
  • OBJECTIVE The definition of a reliable and generally accepted diagnostic standard for perioperative myocardial damage is desirable. Cardiac troponin I (cTnI) is highly specific for myocardial tissueContinue Reading
  • Stephen Y. T. Chan, Max Ernst Scheulen, +17 authors Laurence D. Moore
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Published: 10 August 2005)
  • PURPOSE In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mammalian target of rapamycin, were evaluated for efficacy, safety, and pharmacokinetics in patients with locallyContinue Reading
  • Marcus Schmidt, Max Ernst Scheulen, +8 authors Ahmad Awada
  • Medicine
  • Annals of oncology : official journal of the…
  • 2010 (First Published: 1 February 2010)
  • BACKGROUND High-level expression of epithelial cell adhesion molecule (EpCAM) is associated with unfavorable prognosis in breast cancer. This study was designed to investigate two doses of the fullyContinue Reading
  • Max Ernst Scheulen, Ralf Axel Hilger, +12 authors S J Seeber
  • Medicine
  • Clinical cancer research : an official journal of…
  • 2000 (First Published: 1 November 2000)
  • A Phase I dose escalation and pharmacokinetic study of the alkylating cytotoxic agent treosulfan was conducted to evaluate the maximum tolerated dose and the dose-limiting toxicities in patients withContinue Reading
  • Dietrich W. Beelen, Rudolf Trenschel, +11 authors Ernst Holler
  • Medicine
  • Bone Marrow Transplantation
  • 2005 (First Published: 1 February 2005)
  • Summary:Treosulphan has recently demonstrated antileukaemic activity and potent haematopoietic stem cell toxicity. Dose-escalated treosulphan (3 × 12 or 3 × 14 g/m2) combined with cyclophosphamideContinue Reading
  • Simone Steinbild, Klaus G. Mross, +9 authors Max Ernst Scheulen
  • Medicine
  • British Journal of Cancer
  • 2007 (First Published: 1 December 2007)
  • Sorafenib is a multi-kinase inhibitor with antiangiogenic and antiproliferative activity. The activity of sorafenib in progressive hormone-refractory prostate cancer (HRPC) patients was investigatedContinue Reading
  • Suzanne Leijen, Mark R. Middleton, +13 authors Wilfried Ernst Erich Eberhardt
  • Medicine
  • Clinical cancer research : an official journal of…
  • 2012 (First Published: 1 September 2012)
  • PURPOSE This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicitiesContinue Reading